Abstract 742MO
Background
Recent studies suggest neoadjuvant immune checkpoint blockade (ICB) may be more efficacious than adjuvant treatment in mismatch repair deficient (MMRd) cancers. However, this has not been explored for endometrial cancer (EC). Here, we report results from a phase I feasibility study of neoadjuvant pembrolizumab in 10 MMRd EC patients.
Methods
MMRd EC patients of any stage or grade at intent-to-treat with primary surgery (at least a hysterectomy) were eligible for participation, and 10/10 patients have been recruited. Patients were treated with 2 three-weekly cycles of pembrolizumab monotherapy (200mg iv) prior to standard-of-care resection and adjuvant treatment if indicated. Radiologic and pathologic response rates, treatment-related adverse events (trAEs) and immune correlates of treatment were assessed.
Results
Patients had stage I-II (n=4) or stage III (n=6) disease at diagnosis, remained on-protocol and underwent definitive surgery. In patients with measurable disease on MRI (n=8), a partial radiologic response was observed in 3/8 patients. A pathological response (<90% viable cancer cells) was observed in 5/10 patients, with 2 major pathologic responses (<10% viable cancer cells). To date, no recurrences have been observed, with a median and longest disease-free survival of 17 and 26 months, respectively. Subclonal MMRp was observed in 2 patients after neoadjuvant treatment. 9/10 patients experienced grade 1/2 trAEs. A treatment-induced immunological response was detected in 9/10 patients with increased lymphoid infiltrates, clonal T cell expansion and diverse T cell phenotypes in post-treatment samples. In tumour-draining (sentinel) lymph nodes, significant clonal overlap with treatment-induced intratumoural T cell expansion was demonstrated.
Conclusions
Neoadjuvant ICB is safe and feasible in MMRd EC. Two cycles of pembrolizumab induced pathologic, radiologic and immunologic responses. Investigation of extended neoadjuvant treatment is warranted and currently being evaluated.
Clinical trial identification
NCT04262089, EudraCT 2018-001816-31.
Editorial acknowledgement
Legal entity responsible for the study
UMCG.
Funding
Dutch Cancer Society (drug supply by MSD without funding).
Disclosure
M. de Bruyn: Non-Financial Interests, Institutional, Non-financial benefits, Drug Supply (pembrolizumab): Merck; Financial Interests, Institutional, Research Grant: Genmab, Mendus, BioNovion, Aduro Biotech, Vicinivax; Non-Financial Interests, Institutional, Non-financial benefits, Drug Supply: BioNTech; Financial Interests, Personal, Stocks/Shares: Sairopa. D.N. Church: Non-Financial Interests, Personal, Speaker, Consultant, Advisor, Consultancy for Merck: Merck; Financial Interests, Institutional, Research Funding: Haliodx. V.H. Koelzer: Financial Interests, Institutional, Research Grant: Indica Labs, Roche, Promedica Foundation. M. Jalving: Financial Interests, Institutional, Advisory Board, Advisory Board: AstraZeneca; Financial Interests, Institutional, Advisory Board, Advisory board: Merck. A.K.L. Reyners: Financial Interests, Institutional, Other, Member of the board: Dutch Society of Medical Oncology; Financial Interests, Institutional, Coordinating PI, FIRST study; coordinator for the Netherlands: Tesaro; Financial Interests, Institutional, Local PI, Local PI GCT1015-05 study: Genmab; Financial Interests, Institutional, Local PI, Local PI for the RUBY study: Tesaro; Financial Interests, Institutional, Local PI, Local PI of the R2810 study: Regeneron; Financial Interests, Institutional, Local PI, PI of MK3475-C93 trial: Merck; Non-Financial Interests, Leadership Role, Chairperson of the group that advises the Dutch Society of Medical Oncology whether EMA authorised medication should be common practice in the Netherlands (cieBOM): Dutch Society of Medical Oncology. H.W. Nijman: Non-Financial Interests, Institutional, Non-financial benefits, Drug Supply (pembrolizumab): Merck; Financial Interests, Institutional, Research Grant: Genmab, BioNovion, Aduro Biotech, Vicinivax; Financial Interests, Institutional, Principal Investigator: Mendus; Non-Financial Interests, Institutional, Non-financial benefits, Drug Supply: BioNTech; Financial Interests, Personal, Stocks/Shares: Sairopa, Vicinivax; Financial Interests, Institutional, Advisory Role: Merck; Non-Financial Interests, Personal, Leadership Role, Director Clinical Research: Vicinivax. All other authors have declared no conflicts of interest.
Resources from the same session
LBA43 - Updated response data and analysis of progression free survival by mechanism of mismatch repair loss in endometrial cancer (EC) patients (pts) treated with pembrolizumab plus carboplatin/paclitaxel (CP) as compared to CP plus placebo (PBO) in the NRG GY018 trial
Presenter: Ramez Eskander
Session: Mini oral session - Gynaecological cancers
Resources:
Abstract
Slides
Webcast
740MO - Dostarlimab + chemotherapy for the treatment of primary advanced or recurrent endometrial cancer (pA/rEC): Analysis of progression free survival (PFS) and overall survival (OS) outcomes by molecular classification in the ENGOT-EN6-NSGO/GOG-3031/RUBY trial
Presenter: Mansoor Raza Mirza
Session: Mini oral session - Gynaecological cancers
Resources:
Abstract
Slides
Webcast
741MO - Luveltamab tazevibulin (STRO-002), an anti-folate receptor alpha (FolRα) antibody drug conjugate (ADC), demonstrates clinical activity in recurrent/progressive epithelial endometrial cancer (EEC): STRO-002-GM1 phase I dose expansion
Presenter: Bhavana Pothuri
Session: Mini oral session - Gynaecological cancers
Resources:
Abstract
Slides
Webcast
Invited Discussant LBA43, 740MO, 742MO and 741MO
Presenter: Christian Marth
Session: Mini oral session - Gynaecological cancers
Resources:
Slides
Webcast
743MO - Efficacy and safety of QL1706 plus paclitaxel and cisplatin/carboplatin +/- bevacizumab (Bev) as 1L treatment in recurrent or metastatic cervical cancer (r/mCC): A single-arm, multicenter phase II study
Presenter: Danbo Wang
Session: Mini oral session - Gynaecological cancers
Resources:
Abstract
Slides
Webcast
744MO - AdvanTIG-202: Phase II randomized, multicenter, open-label study of tislelizumab (TIS) with or without ociperlimab (OCI) in patients (pts) with previously treated recurrent/metastatic (R/M) cervical cancer (CC)
Presenter: Jung-Yun Lee
Session: Mini oral session - Gynaecological cancers
Resources:
Abstract
Slides
Webcast
LBA44 - Camrelizumab plus famitinib versus camrelizumab alone and investigator’s choice of chemotherapy in women with recurrent or metastatic cervical cancer
Presenter: Xiaohua Wu
Session: Mini oral session - Gynaecological cancers
Resources:
Abstract
Slides
Webcast
Invited Discussant 743MO, 744MO and LBA44
Presenter: Alexandra Leary
Session: Mini oral session - Gynaecological cancers
Resources:
Slides
Webcast
LBA45 - Overall survival (OS) outcomes from NRG-GY004, a phase III study comparing single-agent olaparib or combination cediranib and olaparib to platinum (Plat) based chemotherapy in recurrent plat sensitive ovarian cancer (OvCa)
Presenter: Joyce Liu
Session: Mini oral session - Gynaecological cancers
Resources:
Abstract
Slides
Webcast
746MO - Randomized phase II trial of durvalumab in combination with olaparib and cediranib (DOC) compared to olaparib and cediranib (OC) or durvalumab and cediranib (DC) or standard of care chemotherapy (SOC) in platinum-resistant ovarian cancer with prior bevacizumab (NRG-GY023)
Presenter: Jung-Min Lee
Session: Mini oral session - Gynaecological cancers
Resources:
Abstract
Slides
Webcast